...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical >Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal
【24h】

Thyroid remnant ablation success and disease outcome in stage III or IV differentiated thyroid carcinoma: recombinant human thyrotropin versus thyroid hormone withdrawal

机译：Ⅲ或Ⅳ期分化型甲状腺癌的甲状腺残余消融成功率和疾病预后：重组人促甲状腺激素与甲状腺激素戒断

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Most publications to date compare outcomes after post-surgical thyroid remnant ablation stimulated by recombinant human thyrotropin (rhTSH) versus thyroid hormone withholding/withdrawal (THW) in low-recurrence risk differentiated thyroid carcinoma (DTC) patients. We sought to perform this comparison in high-risk patients.METHODS: We retrospectively analyzed ~9-year single-center experience in 70 consecutive adults with initial UICC (Union for International Cancer Control) stage III/IV, MO DTC undergoing rhTSH-aided (N.=54) or THW-aided (N.=16) high-activity ablation. Endpoints included ablation success and DTC outcome. Assessed >1 year post-ablation, ablation success comprised a) no visible scintigraphic thyroid bed uptake or pathological extra-thyroidal uptake; b) undetectable stimulated serum thyroglobulin (Tg) without interfering autoantibodies; c) both criteria. DTC outcome, determined at the latest visit, comprised either 1) "no evidence of disease" (NED): undetectable Tg, negative Tg autoantibodies, negative most recent whole-body scan, no suspicious findings clinically, on neck ultrasonography, or on other imaging; 2) persistent disease: failure to attain NED; or 3) recurrence: loss of NED.
机译：背景：迄今为止，大多数出版物比较了低复发风险分化型甲状腺癌（DTC）患者中重组人促甲状腺激素（rhTSH）和甲状腺激素戒断/撤回（THW）刺激的甲状腺残余甲状腺切除术后的结果。方法：我们回顾性分析了70例连续的成人初始UICC（国际癌症控制联盟）III / IV期，MO DTC接受rhTSH辅助的成人的9年单中心经验。 （N. = 54）或THW辅助（N. = 16）高活性消融。终点包括消融成功和DTC结果。在消融后> 1年进行评估，消融成功包括：a）无明显闪烁显像的甲状腺床吸收或病理性甲状腺外吸收; b）在不干扰自身抗体的情况下检测不到刺激的血清甲状腺球蛋白（Tg）; c）两个标准。在最近一次就诊时确定的DTC结果包括：1）“无疾病证据”（NED）：Tg检测不到，Tg自身抗体阴性，最近的全身扫描阴性，临床，颈部超声或其他检查均未发现可疑结果成像2）持续性疾病：未达到NED;或3）复发：NED丢失。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号